Pantoc I.V. (Pantoprazole)

Pantoprazole selectively and irreversibly inhibits the H+/K+‑ATPase enzyme, also known as the gastric proton pump, on the surface of parietal cells. By blocking this final step of acid production, it raises gastric pH, providing effective acid suppression and allowing damaged mucosa to heal.

The appropriate dose of Pantoc I.V. is determined by the prescribing clinician based on the patient’s condition, severity, and renal or hepatic function. Dosing recommendations are provided in the product’s prescribing information and should be individualized for each patient.

Pantoprazole is classified as pregnancy category B, indicating no evidence of risk in animal studies but a lack of well‑controlled human data. It should be used during pregnancy only if clearly needed. Limited data are available for breastfeeding; the decision to continue therapy should weigh potential benefits against possible risks to the infant.

To order Pantoc I.V., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Pantoc I.V. offers rapid, controlled delivery of pantoprazole via the intravenous route, which is advantageous in acute care when oral administration is not feasible. Compared with oral PPIs, it provides faster onset of acid suppression and more predictable plasma concentrations, making it suitable for critically ill patients and those requiring immediate gastric pH control.

Pantoc I.V. must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used promptly and not be re‑refrigerated.

Pantoc I.V. is administered by intravenous infusion, typically diluted in a compatible IV fluid and infused over a few minutes as directed by the prescribing information. Administration should be performed by qualified healthcare professionals in a clinical setting, following aseptic technique and appropriate monitoring.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, rare skin disorders like Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, hepatic dysfunction, and electrolyte disturbances that may lead to cardiac arrhythmias. Prompt recognition and medical intervention are essential if any of these events occur.

Pantoc I.V. is contraindicated in patients with known hypersensitivity to pantoprazole, other proton pump inhibitors, or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, and it should be avoided in individuals with a history of severe allergic reactions to similar drugs.